This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synthesis Polypeptide Drug Market (Global And China) Research Report For 2012

Chapter One Synthesis Polypeptide Drug Industry Overview     1 1.1 Synthesis Polypeptide Drug Definition    1 1.2 Synthesis Polypeptide Drug Classification and Application    3 1.3 Professional Terms Interpretation    8 1.4 Synthesis Polypeptide Drug Industry Chain Structure    12 1.5 Synthesis Polypeptide Drug Industry Overview    14 Chapter Two Synthesis Polypeptide Drug International and China Market Analysis     16 2.1 Synthesis Polypeptide Drug Industry International Market Analysis    16 2.1.1 Synthesis Polypeptide Drug International Market Development History    16 2.1.2 Synthesis Polypeptide Drug Product and Technology Developments    18 2.1.3 Synthesis Polypeptide Drug Competitive Landscape Analysis    25 2.1.4 Synthesis Polypeptide Drug International Key Countries Development Status    28 2.1.5 Synthesis Polypeptide Drug International Market Development Trend    30 2.2 Synthesis Polypeptide Drug China Market Analysis    33 2.2.1 Synthesis Polypeptide Drug China Market Development History    33 2.2.2 Synthesis Polypeptide Drug Product and Technology Developments    33 2.2.3 Synthesis Polypeptide Drug Competitive Landscape Analysis    35 2.2.4 Synthesis Polypeptide Drug China Key Regions Development Status    37 2.2.5 Synthesis Polypeptide Drug China Market Development Trend    37 2.3 Synthesis Polypeptide Drug International and China Market Comparison Analysis    42 Chapter Three Major Synthesis Polypeptide Drug Analysis     43 3.1 Immunity Regulating Medicine (Allergy Infection and Immune)    43 3.1.1 Glatiramer Injection (Glatiramer Acetate)    43 3.1.2 Thymalfasin for Injection    46 3.1.3 Thymopentin Injection    49 3.1.4 Thymopetidum Injection    53 3.1.5 Summary    55 3.2 Digestive System Drugs (Gastrointestinal Type)    57 3.2.1 Octreotide Acetate Injection    57 3.2.2 Somatostatin for Injection    61 3.3 Bone and Connective Tissue Types (Thyroid hormones Drug)    66 3.3.1 Salmon Calcitonin Injection    67 3.3.2 Elcatonin Injection    70 3.3.4 TerfparaLide Injectlon    72 3.4 Gynecologic or Obstetric Drug    76 3.4.1 Oxytocin Injection    76 3.4.2 Carbetocin Injection    81 3.4.3 Acetate Atosiban Injection    83 3.5 Tumor Drug (hCG)    86 3.5.1 Leuprorelin Acetate Microspheres for Injection    87 3.5.2 Goserelin Acetate    89 3.5.3 Triptorelin Acetate Injection    92 3.5.4 Chorionic Gonadotrophin for Injection    95 3.6 Urinary System Drug (Diabetes Insipidus)    98 3.6.1 Desmopressin Acetate Injection    98 3.6.2 Terlipressin for Injection    101 3.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)    105 3.7.1 Biosynthetic Glucagon for Injection    105 3.7.2 Exenatide Injection    106 Chapter Four Synthesis Polypeptide Drug Development Environmental Analysis     109 4.1 China's Macroeconomic Environment Analysis    109 4.1.1 China GDP Analysis    109 4.1.2 China CPI Analysis    111 4.2 European Economic Environmental Analysis and Impact    113 4.3 United States Economic Environmental Analysis and Impact    116 4.4 Japan Economic Environmental Analysis and Impact    119 4.5 Global Economic Environmental Analysis and Impact    120 4.5.1 Global Economic Environmental Analysis    120 4.5.2 Global Economic Influence    121 Chapter Five Synthesis Polypeptide Drug Development Policy and Plan     121 5.1 China Government Policy and Development Plan    121 5.2 Industry Policy and Standard    122 5.3 Technical Standard    125 5.4 Technology Replacement and R&D Trends    126 5.5 Hotspots and Influence    127 Chapter Six Synthesis Polypeptide Drug Manufacturing Process and Cost Structure     132 6.1 Synthesis Polypeptide Drug Manufacturing Process Overview    132 6.2 Synthesis Polypeptide Drug Manufacturing Process Analysis    135 6.3 Synthesis Polypeptide Drug Cost Structure Analysis    138 Chapter Seven 2009-2013 Synthesis Polypeptide Drug Productions Supply Sales Demand Market Status and Forecast     140 7.1 2009-2013 Synthesis Polypeptide Drug Capacity Production Overview    140 7.1.1 2009-2013 Global and China Synthesis Polypeptide Drug Capacity Production    140 7.1.2 2009-2013 Synthesis Polypeptide Drug Production Market Share    146 7.1.3 2009-2013 Synthesis Polypeptide Drug Demand Overview    152 7.1.4 2009-2013 Synthesis Polypeptide Drug Supply Demand and Shortage    152 7.1.5 2009-2013 Synthesis Polypeptide Drug Production Import Export Consumption    153 7.1.6 2009-2013 Synthesis Polypeptide Drug Cost Price Production Value Gross Margin    154 7.2 Different Type Synthesis Polypeptide Drug Sales and Market Scale Analysis    156 7.2.1Thymopentin Injection    156 7.2.2 Thymalfasin Injection    158 7.2.3 Calcitonin Injection    159 7.2.4 Somatostatin for Injection    161 7.2.5Octreotide Acetate Injection    162 7.2.6 Desmopressin Acetate Injection    163 7.3 Synthesis Polypeptide Drug Market Summary    165 Chapter Eight Synthesis Polypeptide Drug Key Manufacturers  ( Company Profiles )    170 8.1 Novartis    170 8.2 Merck Serono    176 8.3 Ferring Pharmaceuticals    181 8.4 Ipsen PHarma Biotech    188 8.5 Lilly    191 8.6 Asahi Kasei    195 8.7 AstraZeneca    199 8.8 SciClone Pharmaceuticals    203 8.9 Takeda    206 8.10 HYBIO Pharmaceutical Co.,Ltd (Shenzhen Stock:300199)    210 8.11 Hainan Zhonghe Pharmaceutical Co.,Ltd    215 8.12 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd    219 8.13 Beijing Yingu Century Pharmaceutical Co.,Ltd (Beijing Shiqiao Bio-Pharmaceutical Co.,Ltd)    224 8.14 Hainan Shuangcheng Pharmaceuticals Co.,Ltd    227 8.15 Livzon Pharmaceuticals Co.,Ltd (Livzon:000513)    234 8.16 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd    238 8.17 Chengdu Tiantaishan Pharmaceutical Co.,Ltd    242 8.18 Beijing Shuanglu Pharmaceutical Co.,Ltd    250 8.19 Yangzijiang Pharmaceutical Co.,Ltd    257 8.20 Changzhou Siyao Pharmaceutical Co.,Ltd    262 Chapter Nine Up and Down Stream Industry Analysis and Influence     267 9.1 Upstream Raw Materials Price Analysis and Influence    267 9.1 Upstream Equipments Market Analysis and Influence    269 9.3 Downstream Demand Analysis and Influence    270 9.4 Industry Policy Analysis and Influence    271 Chapter Ten Synthesis Polypeptide Drug Marketing Channels Analysis     272 10.1 Synthesis Polypeptide Drug Marketing Channels Status    272 10.1.1 Drugs Marketing Channel Developemnt History    272 10.1.1 Prescription Drug Marketing Development Status    273 10.2 Synthesis Polypeptide Drug Marketing Channels Management    274 10.3 Synthesis Polypeptide Drug Marketing Channels Establishment    275 10.4 Synthesis Polypeptide Drug Marketing Channels Development Trend    276 Chapter Eleven Synthesis Polypeptide Drug Industry Development Trend     278 11.1 2012-2016 Synthesis Polypeptide Drug Industry Development Trend    278 11.2 2012-2016 Market Potential Forecast    279 11.3 2012-2016 R&D Trend    280 11.3.1Polypeptide Drug Technical Development Status    280 11.3.2 Polypeptide Drug and Health Care Products Research and Manufacturing Overview    282 11.3.3 China Polypeptide Drug Development Direction and Prospect    283 11.4 2012-2016 Marketing Channels Change Trend    285 14.4.1 Prescription Drug Marketing Channels Change Trend    285 14.4.2 Prescription Drug Sales Method Five Trend    286 11.5 2012-2016 Competition Pattern Development Trends    288 Chapter Twelve Synthesis Polypeptide Drug Industry Development Proposals     289 12.1 Macroeconomic Development Countermeasures    289 12.2 New Firms Enter Market Strategy    290 12.2.1 New Business Entry Barriers    290 12.2.2 New Corporate Strategy    290 12.3 New Project Investment Proposal    293 12.4 Marketing Channel Strategy Proposals    294 12.5 Competitive Environment Strategy Proposals    296 12.5.1 Competitive Environment Analysis    296 12.5.2 Strategy Proposals    297 Chapter Thirteen Synthesis Polypeptide Drug New Project Investment Feasibility Analysis     300 13.1 Synthesis Polypeptide Drug Project SWOT Analysis    300 13.2 Synthesis Polypeptide Drug New Project Investment Feasibility Analysis    302 13.2.1 Buildings    302 13.2.2 Investment    303 13.2.3 Project Schedule    303 13.2.4 Project Investment Return and Feasibility Analysis    304 Chapter Fourteen Synthesis Polypeptide Drug Industry Research Conclusions     304

 

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs